<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00125970</url>
  </required_header>
  <id_info>
    <org_study_id>HVTN 204</org_study_id>
    <secondary_id>10061</secondary_id>
    <nct_id>NCT00125970</nct_id>
  </id_info>
  <brief_title>HVTN Protocol 204 - A Phase II Clinical Trial to Evaluate the Safety and Immunogenicity of a Multiclade HIV-1 DNA Plasmid Vaccine, VRC-HIVDNA016-00-VP, Followed by a Multiclade Recombinant Adenoviral Vector HIV-1 Vaccine Boost, VRCHIVADV014-00-VP, in HIV-1 Uninfected Adult Participants</brief_title>
  <official_title>HVTN Protocol 204 - A Phase II Clinical Trial to Evaluate the Safety and Immunogenicity of a Multiclade HIV-1 DNA Plasmid Vaccine, VRC-HIVDNA016-00-VP, Followed by a Multiclade Recombinant Adenoviral Vector HIV-1 Vaccine Boost, VRCHIVADV014-00-VP, in HIV-1 Uninfected Adult Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine the safety of and immune response to a DNA HIV&#xD;
      vaccine followed by an adenoviral vector HIV vaccine in HIV uninfected adults.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The worldwide HIV/AIDS epidemic may only be controlled through development of a safe and&#xD;
      effective vaccine that will prevent HIV infection. DNA vaccines are inexpensive to construct,&#xD;
      readily produced in large quantities, and stable for long periods of time. This study will&#xD;
      evaluate the safety and immunogenicity of an experimental multiclade HIV vaccine,&#xD;
      VRC-HIVDNA016-00-VP, followed by a similarly structured adenovirus-vectored vaccine boost,&#xD;
      VRC-HIVADV014-00-VP, in HIV uninfected adults. The DNA plasmids in both the vaccines code for&#xD;
      proteins from HIV subtypes A, B, and C, which together represent 90% of new HIV infections in&#xD;
      the world. Participants in this study will be recruited in North America, South America, and&#xD;
      Africa.&#xD;
&#xD;
      Each volunteer will participate in the study for 36 months. Participants will be randomly&#xD;
      assigned to one of two groups. Group 1 participants will receive the DNA HIV vaccine at study&#xD;
      entry and at Months 1 and 2. At Month 6, Group 1 participants will receive an injection of&#xD;
      the adenoviral vector HIV vaccine. Group 2 participants will receive placebo at study entry&#xD;
      and Months 1, 2, and 6. There will be 17 study visits, which will occur at study entry and&#xD;
      every 2 weeks thereafter until Day 70; at Month 6 and every 2 weeks thereafter until Day 210;&#xD;
      and Months 9.5, 12, 18, 24, 30, and 36. A physical exam, adverse events reporting, HIV and&#xD;
      pregnancy prevention counseling, and medication history will occur at each visit. Blood and&#xD;
      urine collection will occur at selected visits.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2005</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">February 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Local and systemic adverse reactions</measure>
    <time_frame>Measured after each injection and for 12 months after the first injection</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Unfractionated IFN-γ ELISpot responses to HIV-1 peptide pools as performed by the VRC laboratory</measure>
    <time_frame>Measured at Day 196</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Unfractionated IFN-γ ELISpot responses to HIV-1 peptide pools as performed by the FHCRC laboratory</measure>
    <time_frame>Measured at Day 210</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>CD4 and CD8 T cell responses to HIV-1 peptide pools as measured by flow cytometry-based intracellular cytokine staining (ICS) assay as performed by the VRC laboratory</measure>
    <time_frame>Measured at Day 196</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>CD4 and CD8 T cell responses to HIV-1 peptide pools as measured by flow cytometry-based ICS assay as performed by the FHCRC laboratory</measure>
    <time_frame>Measured at Day 210</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Humoral immune response to HIV-1 as measured by neutralizing antibody and binding assays</measure>
    <time_frame>Measured through Month 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Unfractionated IFN-γ ELISpot responses to HIV-1 as performed by the FHCRC or the VRC laboratories</measure>
    <time_frame>Measured at Days 70, 210, and 364</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD4 and CD8 T cell responses to HIV-1 as measured by flow cytometry-based ICS assay as performed by the FHCRC or the VRC laboratories</measure>
    <time_frame>Measured at Days 70, 210, and 364</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vaccine-induced HIV-specific T cell responses to individual peptide pools as measured by IFN-γ ELISpot and ICS as performed by the FHCRC or the VRC laboratories</measure>
    <time_frame>Measured through Month 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cross-clade cellular immune responses to HIV-1 Gag-Pol-Nef peptides from clades A and C as assessed by IFN-γ ELISpot and ICS assays as performed by the FHCRC or the VRC laboratories</measure>
    <time_frame>Measured through Month 36</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">480</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DNA HIV vaccine administered at study entry and at Months 1 and 2 and adenoviral vector HIV vaccine administered at Month 6</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>DNA HIV vaccine placebo administered at study entry and at Months 1 and 2 and adenoviral vector HIV vaccine placebo administered at Month 6</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>VRC-HIVDNA016-00-VP</intervention_name>
    <description>4 mg administered in deltoid</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Multiclade HIV-1 DNA Plasmid Vaccine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>VRC-HIVADV014-00-VP</intervention_name>
    <description>1 x 10^10 PU administered in deltoid</description>
    <arm_group_label>1</arm_group_label>
    <other_name>rAD</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>VRC-HIVDNA016-00-VP placebo</intervention_name>
    <description>1 mL administered at study entry and Months 1 and 2</description>
    <arm_group_label>2</arm_group_label>
    <other_name>DNA HIV placebo vaccine</other_name>
    <other_name>Phosphate buffered saline</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>VRC-HIVADV014-00-VP placebo</intervention_name>
    <description>1 mL administered at Month 6</description>
    <arm_group_label>2</arm_group_label>
    <other_name>rAD placebo</other_name>
    <other_name>VRC-DILUENT013-DIL-VP</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  HIV uninfected&#xD;
&#xD;
          -  Has access to a participating HIV Vaccine Trials Unit (HVTU) and willing to be&#xD;
             followed for the duration of the study&#xD;
&#xD;
          -  Willing to receive HIV test results&#xD;
&#xD;
          -  Good general health&#xD;
&#xD;
          -  Willing to use acceptable forms of contraception&#xD;
&#xD;
          -  Completed at least 12 years of schooling (South African participants only)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  HIV vaccines in prior HIV vaccine trial&#xD;
&#xD;
          -  Immunosuppressive medications within 168 days prior to first study vaccine&#xD;
             administration&#xD;
&#xD;
          -  Blood products within 120 days prior to first study vaccine administration&#xD;
&#xD;
          -  Immunoglobulin within 60 days prior to first study vaccine administration&#xD;
&#xD;
          -  Live attenuated vaccines within 30 days prior to first study vaccine administration&#xD;
&#xD;
          -  Investigational research agents within 30 days prior to first study vaccine&#xD;
             administration&#xD;
&#xD;
          -  Subunit or killed vaccines within 14 days prior to first study vaccine administration&#xD;
&#xD;
          -  Current tuberculosis prophylaxis or therapy&#xD;
&#xD;
          -  Clinically significant medical condition, abnormal physical exam findings, abnormal&#xD;
             laboratory results, or past medical history that may affect current health&#xD;
&#xD;
          -  Any medical, psychiatric, or social condition that would interfere with the study.&#xD;
             More information about this criterion can be found in the protocol.&#xD;
&#xD;
          -  Any job-related responsibility that would interfere with the study&#xD;
&#xD;
          -  Serious adverse reaction to vaccines. A person who had an adverse reaction to&#xD;
             pertussis vaccine as a child is not excluded.&#xD;
&#xD;
          -  Autoimmune disease or immunodeficiency&#xD;
&#xD;
          -  Active syphilis infection&#xD;
&#xD;
          -  Unstable asthma&#xD;
&#xD;
          -  Diabetes mellitus type 1 or 2&#xD;
&#xD;
          -  Thyroid disease requiring treatment&#xD;
&#xD;
          -  Serious angioedema within the past 3 years&#xD;
&#xD;
          -  Uncontrolled hypertension&#xD;
&#xD;
          -  Bleeding disorder&#xD;
&#xD;
          -  Cancer. If a participant has had surgery to remove the cancer and, in the opinion of&#xD;
             the investigator, the cancer is not likely to recur during the study period, the&#xD;
             participant is not excluded.&#xD;
&#xD;
          -  Seizure disorder&#xD;
&#xD;
          -  Asplenia&#xD;
&#xD;
          -  Mental illness that would interfere with compliance with the protocol&#xD;
&#xD;
          -  Other conditions that, in the judgment of the investigator, would interfere with the&#xD;
             study&#xD;
&#xD;
          -  Pregnant or breastfeeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Keefer, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Rochester</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gavin Churchyard, MBBCh, FCP, MMed, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Aurum Health Research Limited</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Alabama Vaccine CRS</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294-2041</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Project Brave HIV Vaccine CRS</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hosp. CRS</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miriam Hospital's HVTU</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt Vaccine CRS</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Projeto Praca Onze/Hesfa Crs</name>
      <address>
        <city>Rio de Janeiro</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sao Paulo HVTU - CRT DST/AIDS CRS</name>
      <address>
        <city>San Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Les Centres GHESKIO CRS</name>
      <address>
        <city>Port-au-Prince</city>
        <country>Haiti</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Epidemiology Research &amp; Training Unit Jamaica MOH CRS</name>
      <address>
        <city>Kingston</city>
        <country>Jamaica</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Soweto HVTN CRS</name>
      <address>
        <city>Johannesburg</city>
        <state>Gauteng</state>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emavundleni Desmond Tutu HIV Centre CRS</name>
      <address>
        <city>Cape Town</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CAPRISA Aurum CRS</name>
      <address>
        <city>Klerksdorp</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
    <country>Haiti</country>
    <country>Jamaica</country>
    <country>South Africa</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>United Kingdom</country>
  </removed_countries>
  <link>
    <url>http://aidsinfo.nih.gov/ContentFiles/HIVPreventionVaccines_FS_en.pdf</url>
    <description>Click here for more information on HIV preventive vaccines</description>
  </link>
  <link>
    <url>http://aidsinfo.nih.gov/clinicaltrials/htmltrials_sp.asp?an=1565</url>
    <description>Haga clic aquí para ver información sobre este ensayo clínico en español.</description>
  </link>
  <reference>
    <citation>Esparza J, Osmanov S. HIV vaccines: a global perspective. Curr Mol Med. 2003 May;3(3):183-93. Review.</citation>
    <PMID>12699356</PMID>
  </reference>
  <reference>
    <citation>Gaschen B, Taylor J, Yusim K, Foley B, Gao F, Lang D, Novitsky V, Haynes B, Hahn BH, Bhattacharya T, Korber B. Diversity considerations in HIV-1 vaccine selection. Science. 2002 Jun 28;296(5577):2354-60. Review.</citation>
    <PMID>12089434</PMID>
  </reference>
  <reference>
    <citation>Moore JP, Parren PW, Burton DR. Genetic subtypes, humoral immunity, and human immunodeficiency virus type 1 vaccine development. J Virol. 2001 Jul;75(13):5721-9. Review.</citation>
    <PMID>11390574</PMID>
  </reference>
  <reference>
    <citation>Stratov I, DeRose R, Purcell DF, Kent SJ. Vaccines and vaccine strategies against HIV. Curr Drug Targets. 2004 Jan;5(1):71-88. Review.</citation>
    <PMID>14738219</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>June 30, 2005</study_first_submitted>
  <study_first_submitted_qc>August 1, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 2, 2005</study_first_posted>
  <disposition_first_submitted>January 30, 2010</disposition_first_submitted>
  <disposition_first_submitted_qc>January 30, 2010</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">February 2, 2010</disposition_first_posted>
  <last_update_submitted>October 13, 2021</last_update_submitted>
  <last_update_submitted_qc>October 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV Seronegativity</keyword>
  <keyword>HIV Preventive Vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

